8-K: CAMP4 Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 Therapeutics announced its full year 2024 financial results, provided a corporate update, and highlighted the progress of its clinical programs and research collaborations.

Summary

• CAMP4 Therapeutics Corporation (CAMP4) announced its financial results for the year ended December 31, 2024, and provided a corporate update.
• The company is focused on its Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) and plans to expand into a Phase 1b clinical trial in female OTC heterozygotes in Australia, with a Clinical Trial Application (CTA) planned for Europe.
• CAMP4 nominated CMP-SYNGAP-01 as a development candidate for SYNGAP1-related disorders.
• Research and development expenses for 2024 were $38.8 million, compared to $40.6 million in 2023.
• General and administrative expenses for 2024 were $14.9 million, compared to $11.6 million in 2023.
• The net loss for 2024 was $51.8 million, compared to $49.3 million in 2023.
• As of December 31, 2024, cash and cash equivalents totaled approximately $64.0 million, which the company believes will be sufficient to fund its planned activities into Q2 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress in its clinical programs and has sufficient cash to fund operations into Q2 2026. However, the company is still incurring significant losses, which tempers the overall positive outlook.

Positives

• The Phase 1 clinical trial of CMP-CPS-001 showed favorable safety results in healthy volunteers.
• The company is expanding its clinical program to include female OTC heterozygotes, an underserved patient population.
• A development candidate, CMP-SYNGAP-01, has been nominated for SYNGAP1-related disorders.
• The company has initiated a discovery program for GBA1-related Parkinson's Disease.
• The company believes its current cash and cash equivalents will be sufficient to fund its planned activities into Q2 2026.

Negatives

• The company experienced a net loss of $51.8 million for the year ended December 31, 2024.
• The company has incurred substantial losses since its inception and anticipates incurring increasing losses for the foreseeable future.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to significant clinical development risks.
• The company needs substantial additional financing to achieve its goals.
• There are risks related to delays or difficulties in the enrollment and dosing of patients in clinical trials.
• The company faces potential competition from large and specialty pharmaceutical and biotechnology companies.
• The company's ability to obtain regulatory approval to commercialize any product candidate is uncertain.

Future Outlook

CAMP4 expects to initiate a Phase 1b clinical trial of CMP-CPS-001 in female OTC heterozygotes in Q2 2025 and anticipates data from the CMP-CPS-001 clinical trials in Q4 2025. The company also plans to initiate GLP toxicity studies for its SYNGAP1 program this year and advance a new discovery program targeting a GBA1 regRNA for Parkinson's disease.

Management Comments

• We are off to a strong start in 2025, building on the momentum of a successful 2024, which included advancing our Phase 1 clinical program in UCDs, establishing key research collaborations, securing important regulatory designations, and completing our initial public offering, said Josh Mandel-Brehm, Chief Executive Officer of CAMP4.
• We remain focused on the ongoing healthy volunteer Phase 1 clinical trial of CMP-CPS-001 in UCDs, as well as our planned expansion into a Phase 1b clinical trial in Australia in female OTC heterozygotes a potential additional addressable patient population of UCDs that has previously been underserved.
• We are also pleased to announce the selection of a development candidate, CMP-SYNGAP-01, for our SYNGAP1-related disorders program based on compelling data across our preclinical studies, including recent non-human primate studies.
• Recent research shows that many of these women face chronic, underrecognized symptoms and serious health risks, including the danger of hyperammonemic crises triggered by stress, illness, pregnancy or surgery, said Dr. Yuri Maricich, Chief Medical Officer of CAMP4.
• CAMP4s Phase1b clinical trial represents a crucial step forward in redefining care for female OTC heterozygotes moving from passive observation to proactive monitoring and treatment.

Industry Context

CAMP4's focus on regulatory RNA-targeting therapeutics represents a novel approach in the treatment of genetic diseases. The company's pipeline targets diseases with limited or no approved therapies, addressing unmet medical needs. The expansion into female OTC heterozygotes highlights a growing awareness of the importance of addressing previously underserved patient populations in rare genetic disorders.

Comparison to Industry Standards

• The safety profile of CMP-CPS-001 in the Phase 1 trial is consistent with approved liver-targeted ASOs, suggesting a favorable safety profile compared to other similar therapies.
• The company's focus on SYNGAP1-related disorders aligns with the increasing interest in developing targeted therapies for neurodevelopmental conditions, similar to efforts by companies like Roche and Novartis in other neurological disorders.
• CAMP4's approach to upregulate gene expression using regRNA-targeting ASOs is a unique strategy compared to traditional gene therapy or gene editing approaches used by companies like Sarepta Therapeutics and CRISPR Therapeutics.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and financial stability are positive for shareholders.
• Patients: The development of new therapies for genetic diseases could improve the lives of patients and their families.
• Employees: The company's growth and expansion provide opportunities for employees.
• Partners: The company's strategic partnerships are important for maximizing the value of its RAP Platform.

Next Steps

• Initiate expansion into Phase 1b clinical trial of CMP-CPS-001 in female OTC heterozygotes in Q2 2025.
• Submit a Clinical Trial Application (CTA) in Europe.
• Initiate GLP toxicity studies of CMP-SYNGAP-01.
• Advance a new discovery program targeting a GBA1 regRNA to increase gene expression for the treatment of Parkinson's disease.

Key Dates

Keywords

CAMP4 Therapeutics, CMP-CPS-001, CMP-SYNGAP-01, Urea Cycle Disorders, SYNGAP1, GBA1, Parkinson's Disease, regRNA, Clinical Trial, Financial Results, Biopharmaceutical, Gene Expression, Genetic Diseases, Phase 1b, OTC heterozygotes